ArticleDrug design, development and therapy2026
Efficacy and Safety of Everolimus in Advanced Unresectable and Progressive Epithelioid Hemangioendothelioma: A Single-Center Case Series.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelioid hemangioendothelioma (EHE) is an ultra-rare vascular sarcoma, with the liver and lungs as the predominant primary sites. To date, no standard systemic therapy has been established for advanced EHE. This study aimed to evaluate the efficacy and safety of everolimus in patients with advanced, unresectable, and progressive EHE. Methods: This case series retrospectively included 11 patients with advanced, progressive EHE who received systemic therapy with everolimus at our hospital spanning a 3-year period. The clinical outcomes, including time to treatment failure (TTF), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs), were analyzed. The median follow-up time was estimated using the reverse Kaplan-Meier method. Results: At the data cutoff (April 11, 2025), the median follow-up time was 21.9 months. The median TTF was 21.3 months, and median OS was not reached at the time of analysis. All 11 cases achieved stable disease (SD); the ORR was 0% (0/11), and the DCR was 100.0% (11/11). The most common AEs were mucositis accompanied by multiple oral ulcers (54.5%), which was limited to grade 1-2 severity. One patient (9.1%) experienced grade 3 upper gastrointestinal bleeding. Other AEs included interstitial pneumonia (27.3%), rash (18.2%), and thrombocytopenia (18.2%). No grade 4 or 5 AEs were observed. Conclusion: Everolimus showed preliminary activity, primarily disease stabilisation, in this small retrospective case series of patients with advanced, unresectable, and progressive EHE. Further studies with larger cohorts are warranted to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.